ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2024

Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors.

Jialin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.